VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy

Michael N. Dudley, PharmD, senior vice president and head of R&D at the Medicines Company, discusses the results of the TANGO II study of VABOMERE, a new beta-lactam that combines meropenem and vaborbactam. In patients with carbapenem-resistant Enterobacteriaceae (CRE), VABOMERE was associated with a higher overall cure and lower mortality compared with the best available therapy.